Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency
Sponsor: Novo Nordisk A/S
Listed as NCT00184769, this PHASE4 trial focuses on Chronic Kidney Disease and Chronic Renal Insufficiency and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 7 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Mar 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Mar 2017 [monthly]
Completed PHASE4
First recorded
Jan 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badajoz, Spain , Barakaldo, Spain , Coimbra, Portugal , Esplugues Llobregat, Spain , Lisbon, Portugal , Lugo, Spain , Madrid, Spain , Málaga, Spain , Oviedo, Spain , Pamplona, Spain and 7 more locations